OncoMatch/Clinical Trials/NCT06115902
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Is NCT06115902 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TQB2102 for for breast cancer.
Treatment: TQB2102 for — TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 1/Phase 2 study to evaluate the effectiveness, safety, pharmacokinetics (PK) and anti-drug antibody (ADA) of TQB2102 for injection in subjects with HER2-expressing relapsed/metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) expression
Breast cancer patients diagnosed with HER2 expression by pathological examination
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior antitumor therapy
Disease progression or intolerance during or after the most recent treatment period must be present before participating in clinical trials
Cannot have received: chemotherapy
Patients who have been treated with other antitumor drug, such as chemotherapy, radical radiotherapy, or immunotherapy, within 4 weeks prior to the first dose, or who are still within 5 half-lives of the drug
Cannot have received: radical radiotherapy
Patients who have been treated with other antitumor drug, such as chemotherapy, radical radiotherapy, or immunotherapy, within 4 weeks prior to the first dose, or who are still within 5 half-lives of the drug
Cannot have received: immunotherapy
Patients who have been treated with other antitumor drug, such as chemotherapy, radical radiotherapy, or immunotherapy, within 4 weeks prior to the first dose, or who are still within 5 half-lives of the drug
Cannot have received: Chinese patent drugs with anti-tumor indications
Received Chinese patent drugs with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 week before the study treatment
Cannot have received: other anti-tumor clinical trial therapy
Patients who participated in and used other anti-tumor clinical trials within 4 weeks before the first medication
Lab requirements
Blood counts
Kidney function
Liver function
The main organs function are normally
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify